| Bioactivity | Gatipotuzumab (PankoMab) is a humanized monoclonal antibody which recognizes the tumor-specific epitope of mucin-1 (TA-MUC1). Gatipotuzumab reveals a potent tumor-specific antibody-dependent cell cytotoxicity (ADCC)[1][2]. |
| Target | MUC1 |
| Invitro | Gatipotuzumab (PankoMab) 在 PDTRP 序列的 T 位点被 GalNAcα 糖基化时，强烈结合由 30 个氨基酸组成的 1.5 TRs 的短 MUC1 肽，但如果相同的肽没有糖基化时则不会结合[2]。Gatipotuzumab (PankoMab) (1 h) 对肿瘤细胞具有高亲和力 (对 NM-D4、ZR75-1、MCF-7 和 T-47D 的 KD 分别为 0.91、3.03、3.84 和 7.14 nM)[2]。Gatipotuzumab (PankoMab) (0-5 μg/mL; 4 h) 显示特异性的抗肿瘤抗体依赖细胞细胞毒活性[2]。 |
| Name | Gatipotuzumab |
| CAS | 1264737-26-9 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Macchini M, et al. Results from the primary analysis of a 30 patient extension of the GATTO study, a phase Ib study combining the anti-MUC1 gatipotuzumab (GAT) with the anti-EGFR tomuzotuximab (TO) or panitumumab in patients with refractory solid tumors. European Journal of Cancer, 2020, 138: S5-S6. [2]. Danielczyk A, et al. PankoMab: a potent new generation anti-tumour MUC1 antibody. Cancer Immunol Immunother. 2006 Nov;55(11):1337-47. |